Table of Contents Author Guidelines Submit a Manuscript
Obstetrics and Gynecology International
Volume 2013, Article ID 383278, 6 pages
http://dx.doi.org/10.1155/2013/383278
Clinical Study

Discrepancies between Antimullerian Hormone and Follicle Stimulating Hormone in Assisted Reproduction

1St. Michael’s Hospital, University Hospital Bristol NHS Foundation Trust, Southwell Street Bristol, BS2 8EG, UK
2University of Bristol, St. Michael's Hospital, Bristol BS2 8EG, UK
3Southmead Hospital, North Bristol NHS Trust & Bristol Centre for Reproductive Medicine Bristol, Southmead Road, Westbury-on-Trym, Bristol BS10 5NB, UK

Received 16 September 2013; Accepted 31 October 2013

Academic Editor: Enrique Hernandez

Copyright © 2013 Munawar Hussain et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. J. Broekmans, J. Kwee, D. J. Hendriks, B. W. Mol, and C. B. Lambalk, “A systematic review of tests predicting ovarian reserve and IVF outcome,” Human Reproduction Update, vol. 12, no. 6, pp. 685–718, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. S. L. Broer, B. W. J. Mol, D. Hendriks, and F. J. M. Broekmans, “The role of antiMüllerian hormone in prediction of outcome after IVF: comparison with the antral follicle count,” Fertility and Sterility, vol. 91, no. 3, pp. 705–714, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. A. La Marca, G. Sighinolfi, D. Radi et al., “Anti-Müllerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART),” Human Reproduction Update, vol. 16, no. 2, Article ID dmp036, pp. 113–130, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. E. F. Wolff and H. S. Taylor, “Value of the day 3 follicle-stimulating hormone measurement,” Fertility and Sterility, vol. 81, no. 6, pp. 1486–1488, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. D. J. Cahill, C. J. Prosser, P. G. Wardle, W. C. L. Ford, and M. G. R. Hull, “Relative influence of serum follicle stimulating hormone, age and other factors on ovarian response to gonadotrophin stimulation,” British Journal of Obstetrics and Gynaecology, vol. 101, no. 11, pp. 999–1002, 1994. View at Google Scholar · View at Scopus
  6. M. A. Esposito, C. Coutifaris, and K. T. Barnhart, “A moderately elevated day 3 FSH concentration has limited predictive value, especially in younger women,” Human Reproduction, vol. 17, no. 1, pp. 118–123, 2002. View at Google Scholar · View at Scopus
  7. J. P. Toner, C. B. Philput, G. S. Jones, and S. J. Muasher, “Basal follicle-stimulating hormone level is a better predictor of in vitro fertilization performance than age,” Fertility and Sterility, vol. 55, no. 4, pp. 784–791, 1991. View at Google Scholar · View at Scopus
  8. W. J. K. Hehenkamp, C. W. N. Looman, A. P. N. Themmen, F. H. De Jong, E. R. Te Velde, and F. J. M. Broekmans, “Anti-Müllerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 10, pp. 4057–4063, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. A. La Marca, S. Giulini, A. Tirelli et al., “Anti-Müllerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology,” Human Reproduction, vol. 22, no. 3, pp. 766–771, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. R. A. Anderson, S. M. Nelson, and W. H. B. Wallace, “Measuring anti-Müllerian hormone for the assessment of ovarian reserve: when and for whom is it indicated?” Maturitas, vol. 71, no. 1, pp. 28–33, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. S. M. Nelson, R. W. Yates, and R. Fleming, “Serum anti-Müllerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles—implications for individualization of therapy,” Human Reproduction, vol. 22, no. 9, pp. 2414–2421, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. S. M. Nelson, R. W. Yates, H. Lyall et al., “Anti-Müllerian hormone-based approach to controlled ovarian stimulation for assisted conception,” Human Reproduction, vol. 24, no. 4, pp. 867–875, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. L. G. Nardo, R. Fleming, C. M. Howles et al., “Conventional ovarian stimulation no longer exists: welcome to the age of individualized ovarian stimulation,” Reproductive BioMedicine Online, vol. 23, no. 2, pp. 141–148, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. A. P. Yates, O. Rustamov, S. A. Roberts et al., “Anti-Müllerian hormone-tailored stimulation protocols improve outcomes whilst reducing adverse effects and costs of IVF,” Human Reproduction, vol. 26, no. 9, pp. 2353–2362, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. D. M. Wunder, N. A. Bersinger, M. Yared, R. Kretschmer, and M. H. Birkhäuser, “Statistically significant changes of anti-Müllerian hormone and inhibin levels during the physiologic menstrual cycle in reproductive age women,” Fertility and Sterility, vol. 89, no. 4, pp. 927–933, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Overbeek, F. J. Broekmans, W. J. Hehenkamp et al., “Intra-cycle fluctuations of anti-Müllerian hormone in normal women with a regular cycle: a re-analysis,” Reproductive BioMedicine Online, vol. 24, pp. 664–669, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. T. Singer, D. H. Barad, A. Weghofer, and N. Gleicher, “Correlation of anti-Müllerian hormone and baseline follicle-stimulating hormone levels,” Fertility and Sterility, vol. 91, no. 6, pp. 2616–2619, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. N. Gleicher, A. Weghofer, and D. H. Barad, “Discordances between follicle stimulating hormone (FSH) and anti-Müllerian hormone (AMH) in female infertility,” Reproductive Biology and Endocrinology, vol. 8, article 64, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. B. Leader, A. Hegde, Q. Baca et al., “High frequency of discordance between anti-Müllerian hormone and follicle-stimulating hormone levels in serum from estradiol-confirmed days 2 to 4 of the menstrual cycle from 5,354 women in U.S. fertility centers,” Fertility and Sterility, vol. 98, pp. 1037–1042, 2012. View at Publisher · View at Google Scholar
  20. T. Molinaro and A. Samra, “Patients with discordant AMH and FSH have a better prognosis in in-vitro fertilization than those with two abnormal markers of ovarian reserve,” Fertility and Sterility, vol. 96, supplement, p. S199, 2011. View at Google Scholar
  21. S. M. Nelson, R. A. Anderson, F. J. Broekmans, N. Raine-Fenning, R. Fleming, and A. La Marca, “Anti-Müllerian hormone: clairvoyance or crystal clear?” Human Reproduction, vol. 27, no. 3, pp. 631–636, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Weghofer, W. Dietrich, D. H. Barad, and N. Gleicher, “Live birth chances in women with extremely low-serum anti-Müllerian hormone levels,” Human Reproduction, vol. 26, no. 7, pp. 1905–1909, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. C. Kailasam, L. P. Hunt, I. Ryder, I. Bhakri, and U. D. Gordon, “Safety and effectiveness of diclofenac sodium in assisted reproduction treatment: a randomized prospective double-blind study,” Reproductive BioMedicine Online, vol. 16, no. 5, pp. 724–729, 2008. View at Google Scholar · View at Scopus
  24. E. Buyuk, D. B. Seifer, J. Younger, R. V. Grazi, and H. Lieman, “Random anti-Müllerian hormone (AMH) is a predictor of ovarian response in women with elevated baseline early follicular follicle-stimulating hormone levels,” Fertility and Sterility, vol. 95, no. 7, pp. 2369–2372, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. N. Gleicher, A. Weghofer, and D. H. Barade, “Clinical significance of concordances and discordances between follicle stimulating hormone (FSH) and anti-mullerian hormone (AMH) in assessment of ovarian reserve (OR),” Fertility and Sterility, vol. 94, supplement, no. 4, p. 85, 2010. View at Publisher · View at Google Scholar
  26. B. Leader, Q. Baca, D. Seifer, and V. L. Baker, “Discordance between antimullerain hormone (AMH) and day 3 follicle stimulating hormone (FSH) levels in the assessment of ovarian reserve,” Fertility and Sterility, vol. 94, supplement, p. S23, 2010. View at Google Scholar
  27. I. Park, K. H. Lee, H. G. Sun, S. K. Kim, J. H. Lee, and G. H. Leon, “High accuracy of IVF prognosis attained using a combination of AMH and day 3 FSH/LH ratio,” Fertility and Sterility, vol. 96, supplement, p. S190, 2011. View at Google Scholar
  28. I. D. Harris, S. Wang, L. Roth, R. Alvero, P. McShane, and W. D. Schlaff, “When antimullerain hormone and follicle stimulating hormone offer a discrepent prognosis of ovarian reserve, in vitro fertilization outcomes are worse than when both values predict poor ovarian reserve,” Fertility and Sterility, vol. 94, supplement, p. S26, 2010. View at Google Scholar
  29. A. La Marca, G. Stabile, A. Carducci Artenisio, and A. Volpe, “Serum anti-Müllerian hormone throughout the human menstrual cycle,” Human Reproduction, vol. 21, no. 12, pp. 3103–3107, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. O. Rustamov, A. Smith, S. A. Roberts et al., “Anti-Müllerian hormone: poor assay reproducibility in a large cohort of subjects suggests sample instability,” Human Reproduction, vol. 27, pp. 3085–3091, 2012. View at Google Scholar
  31. H. Abdallah and Y. Thum, “Association of AMH and FSH levels with IVF treatment,” Fertility and Sterility, vol. 90, supplement, p. 405, 2008. View at Google Scholar
  32. S. D. Harlow, M. Gass, J. E. Hall et al., “Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging,” Menopause, vol. 19, no. 4, pp. 387–395, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. N. Gleicher, A. Weghofer, and D. H. Barad, “Anti-Müllerian hormone (AMH) defines, independent of age, low versus good live-birth chances in women with severely diminished ovarian reserve,” Fertility and Sterility, vol. 94, no. 7, pp. 2824–2827, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. R. K. K. Lee, F. S. Y. Wu, M.-H. Lin, S.-Y. Lin, and Y.-M. Hwu, “The predictability of serum anti-Müllerian level in IVF/ICSI outcomes for patients of advanced reproductive age,” Reproductive Biology and Endocrinology, vol. 9, article 115, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. B. Friden, P. Sjoblom, and J. Menzes, “Using anti-Müllerian hormone to identify a good prognosis group in women of advanced reproductive age,” Australian and New Zealand Journal of Obstetrics and Gynaecology, vol. 51, pp. 411–415, 2011. View at Google Scholar
  36. N. Gleicher and D. H. Barad, “Dehydroepiandrosterone (DHEA) supplementation in diminished ovarian reserve (DOR),” Reproductive Biology and Endocrinology, vol. 9, article 67, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. A. Hazout, P. Bouchard, D. B. Seifer, P. Aussage, A. M. Junca, and P. Cohen-Bacrie, “Serum anti-Müllerian hormone/Müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol,” Fertility and Sterility, vol. 82, no. 5, pp. 1323–1329, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. D. N. Lekamge, M. Barry, M. Kolo, M. Lane, R. B. Gilchrist, and K. P. Tremellen, “Anti-Müllerian hormone as a predictor of IVF outcome,” Reproductive BioMedicine Online, vol. 14, no. 5, pp. 602–610, 2007. View at Google Scholar · View at Scopus
  39. J. M. J. Smeenk, F. C. G. J. Sweep, G. A. Zielhuis, J. A. M. Kremer, C. M. G. Thomas, and D. D. M. Braat, “Anti-Müllerian hormone predicts ovarian responsiveness, but not embryo quality or pregnancy, after in vitro fertilization or intracyoplasmic sperm injection,” Fertility and Sterility, vol. 87, no. 1, pp. 223–226, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. S. L. Fong, E. B. Baart, E. Martini et al., “Anti-Müllerian hormone: a marker for oocyte quantity, oocyte quality and embryo quality?” Reproductive BioMedicine Online, vol. 16, no. 5, pp. 664–670, 2008. View at Google Scholar · View at Scopus
  41. K. Tremellen and M. Kolo, “Serum anti-Müllerian hormone is a useful measure of quantitative ovarian reserve but does not predict the chances of live-birth pregnancy,” Australian and New Zealand Journal of Obstetrics and Gynaecology, vol. 50, no. 6, pp. 568–572, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. V. Grzegorczyk-Martin, M. Khrouf, S. Bringer-Deutsch et al., “Low circulating anti-Müllerian hormone and normal follicle stimulating hormone levels: which prognosis in an IVF program?” Gynécologie Obstétrique & Fertilité, vol. 40, no. 7-8, pp. 411–418, 2012. View at Publisher · View at Google Scholar